Analysis of the efficacy and safety of trastuzumab combined with apatinib in the treatment of advanced breast cancer

Ma Shang; Xia Haishui; Yu Dehai; Tang Lanqing; Lu Biao; Xu Zeming; Wang Wei

doi:10.3760/j.issn.1673-4777.2024.12.011

Abstract：Objective To investigate the efficacy and safety of trastuzumab combined with apatinib in the treatment of advanced breast cancer.Methods A total of 128 patients with advanced breast cancer admitted to Cangzhou People's Hospital,Hebei Province from January 2022 to February 2024 were selected and divided into observation group and control group by random number table method,with 64 cases in each group.The control group was treated with trastuzumab,and the observation group was treated with apatinib on the basis of the control group.The clinical efficacy,biochemical indexes,serum tumor markers,quality of life and adverse reactions were compared between the two groups.Results The total effective rate and disease control rate of the observation group were higher than those of the control group[29.7％(19/64)vs 12.5％(8/64),60.9％(39/64)vs 34.4％(22/64)](x2=5.680,P＜0.001;x2=9.051,P=0.003).After treatment,the levels of platelet factor 4,midkine,carcinoembryonic antigen,tissue polypeptide specific antigen,carbohydrate antigen 125 and carbohydrate antigen 153 in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).After treatment,the quality of life scores of the two groups were higher than those before treatment,and that in the observation group was higher than that in the control group(all P＜0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Trastuzumab combined with apatinib is effective and safe in the treatment of advanced breast cancer,which can significantly reduce the level of tumor markers and improve the quality of life of patients.